These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 8542915)

  • 1. Lymphocytapheresis in combination with immunosuppressive drugs for refractory myasthenia gravis: two-color flow cytometric analysis of changes in peripheral blood lymphocyte subsets.
    Furutama D; Nakajima H; Shinoda K; Makino S; Ohsawa N
    Eur Neurol; 1995; 35(5):270-5. PubMed ID: 8542915
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating and thymic CD4 CD25 T regulatory cells in myasthenia gravis: effect of immunosuppressive treatment.
    Fattorossi A; Battaglia A; Buzzonetti A; Ciaraffa F; Scambia G; Evoli A
    Immunology; 2005 Sep; 116(1):134-41. PubMed ID: 16108825
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma exchange combined with cytotoxic drugs and lymphocytapheresis for myasthenia gravis.
    Valbonesi M; Garelli S; Zerbi D; Forlani G; Cornelio F; Pelucchetti D
    Vox Sang; 1982; 43(3):142-6. PubMed ID: 7147857
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Myasthenia Gravis Study Group.
    Palace J; Newsom-Davis J; Lecky B
    Neurology; 1998 Jun; 50(6):1778-83. PubMed ID: 9633727
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Myasthenia gravis. Immunological studies in a young child treated with thymectomy and immunosuppressive drugs.
    Bjerre I; Hallberg A
    Neuropediatrics; 1983 May; 14(2):106-9. PubMed ID: 6603592
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of thymectomy on human peripheral blood T cell pools in myasthenia gravis.
    Sempowski G; Thomasch J; Gooding M; Hale L; Edwards L; Ciafaloni E; Sanders D; Massey J; Douek D; Koup R; Haynes B
    J Immunol; 2001 Feb; 166(4):2808-17. PubMed ID: 11160348
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma exchange and immunosuppressive drug treatment in myasthenia gravis: no evidence for synergy.
    Hawkey CJ; Newsom-Davis J; Vincent A
    J Neurol Neurosurg Psychiatry; 1981 Jun; 44(6):469-75. PubMed ID: 7276959
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A decrease in the percentage of CD3+ cells is correlated with clinical improvement during plasmapheresis in patients with myasthenia gravis.
    Chien PJ; Yeh JH; Shih CM; Hsueh YM; Chen MC; Chiu HC
    Artif Organs; 2013 Feb; 37(2):211-6. PubMed ID: 23020831
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of T cell subpopulations and recombinant interleukin (IL)-2 on peripheral B cell function in patients with myasthenia gravis.
    Zhang J; Zhou WB; Wang HL; Guo SS
    Hum Antibodies; 1997; 8(2):90-4. PubMed ID: 9289393
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD4
    Kohler S; Keil TOP; Hoffmann S; Swierzy M; Ismail M; Rückert JC; Alexander T; Meisel A
    Clin Immunol; 2017 Jun; 179():40-46. PubMed ID: 28286113
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thymectomy and azathioprine have no effect on the phenotype of CD4 T lymphocyte subsets in myasthenia gravis.
    Melms A; Malcherek G; Gern U; Sommer N; Weissert R; Wiethölter H; Bühring HJ
    J Neurol Neurosurg Psychiatry; 1993 Jan; 56(1):46-51. PubMed ID: 8094093
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term treatment of myasthenia gravis with immunoadsorption.
    Haas M; Mayr N; Zeitlhofer J; Goldammer A; Derfler K
    J Clin Apher; 2002; 17(2):84-7. PubMed ID: 12210711
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bone density in myasthenia gravis patients receiving long-term prednisolone therapy.
    Wakata N; Nemoto H; Sugimoto H; Nomoto N; Konno S; Hayashi N; Araki Y; Nakazato A
    Clin Neurol Neurosurg; 2004 Mar; 106(2):139-41. PubMed ID: 15003307
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lymphocyte subsets of the peripheral blood in myasthenia gravis determined by two-color flow cytometry.
    Shimizu H; Ichikawa Y; Yoshida M; Takahashi K; Arimori S
    Autoimmunity; 1990; 6(3):173-82. PubMed ID: 2129775
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Anti-acetylcholine receptor antibodies: effect of immunosuppressive drug therapy in patients with myasthenia gravis].
    Sidnev DV; Sanadze AG; Dedaev SI; Karganov MIu; Alchinova IB
    Zh Nevrol Psikhiatr Im S S Korsakova; 2010; 110(11 Pt 1):37-40. PubMed ID: 21183922
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Therapy for anti-MuSK antibody positive myasthenia gravis].
    Pál Z; Boczán J; Bereznai B; Lovas G; Molnár MJ
    Orv Hetil; 2011 Sep; 152(39):1586-9. PubMed ID: 21920845
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Effects of thymectomy and glucocorticoid therapy on peripheral lymphocytes in myasthenia gravis].
    Huang Y; Xu X; Lin J
    Zhonghua Nei Ke Za Zhi; 1995 Aug; 34(8):514-7. PubMed ID: 8697907
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasmapheresis in myasthenia gravis.
    Dau PC
    Prog Clin Biol Res; 1982; 88():265-85. PubMed ID: 7100216
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Changes in clinical and immunological status after post-thymectomized irradiation for invasive thymoma with myasthenia gravis].
    Ishida S
    Rinsho Shinkeigaku; 1996 May; 36(5):629-32. PubMed ID: 8905980
    [TBL] [Abstract][Full Text] [Related]  

  • 20. P-glycoprotein function in peripheral T lymphocyte subsets of myasthenia gravis patients: clinical implications and influence of glucocorticoid administration.
    Tanaka S; Masuda M; Nakajima K; Ido N; Ohtsuka T; Nishida M; Utsumi H; Hirano T
    Int Immunopharmacol; 2009 Mar; 9(3):284-90. PubMed ID: 19101657
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.